Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine.

Ferro R, Adamska A, Lattanzio R, Mavrommati I, Edling CE, Arifin SA, Fyffe CA, Sala G, Sacchetto L, Chiorino G, De Laurenzi V, Piantelli M, Sansom OJ, Maffucci T, Falasca M.

Oncogene. 2018 Jul 30. doi: 10.1038/s41388-018-0390-1. [Epub ahead of print]

PMID:
30061636
2.

Transcriptional remodeling in primary hippocampal astrocytes from an Alzheimer's disease mouse model.

Ruffinatti F, Tapella L, Gregnanin I, Stevano A, Chiorino G, Canonico PL, Distasi C, Genazzani AA, Lim D.

Curr Alzheimer Res. 2018 Jun 12. doi: 10.2174/1567205015666180613113924. [Epub ahead of print]

PMID:
29895250
3.

Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma.

Peraldo-Neia C, Ostano P, Cavalloni G, Pignochino Y, Sangiolo D, De Cecco L, Marchesi E, Ribero D, Scarpa A, De Rose AM, Giuliani A, Calise F, Raggi C, Invernizzi P, Aglietta M, Chiorino G, Leone F.

BMC Genomics. 2018 Jun 5;19(1):440. doi: 10.1186/s12864-018-4829-0.

4.

Cross-Talk between Myeloid-Derived Suppressor Cells and Mast Cells Mediates Tumor-Specific Immunosuppression in Prostate Cancer.

Jachetti E, Cancila V, Rigoni A, Bongiovanni L, Cappetti B, Belmonte B, Enriquez C, Casalini P, Ostano P, Frossi B, Sangaletti S, Chiodoni C, Chiorino G, Pucillo CE, Tripodo C, Colombo MP.

Cancer Immunol Res. 2018 May;6(5):552-565. doi: 10.1158/2326-6066.CIR-17-0385. Epub 2018 Mar 9.

PMID:
29523597
5.

Truncating mutations of TP53AIP1 gene predispose to cutaneous melanoma.

Benfodda M, Gazal S, Descamps V, Basset-Seguin N, Deschamps L, Thomas L, Lebbe C, Saiag P, Zanetti R, Sacchetto L, Chiorino G, Scatolini M, Grandchamp B, Bensussan A, Soufir N.

Genes Chromosomes Cancer. 2018 Jun;57(6):294-303. doi: 10.1002/gcc.22528. Epub 2018 Feb 21.

PMID:
29359367
6.

The ANDROMEDA prospective cohort study: predictive value of combined criteria to tailor breast cancer screening and new opportunities from circulating markers: study protocol.

Giordano L, Gallo F, Petracci E, Chiorino G, Segnan N; Andromeda working group.

BMC Cancer. 2017 Nov 22;17(1):785. doi: 10.1186/s12885-017-3784-5.

7.

The IKK/NF-κB signaling pathway requires Morgana to drive breast cancer metastasis.

Fusella F, Seclì L, Busso E, Krepelova A, Moiso E, Rocca S, Conti L, Annaratone L, Rubinetto C, Mello-Grand M, Singh V, Chiorino G, Silengo L, Altruda F, Turco E, Morotti A, Oliviero S, Castellano I, Cavallo F, Provero P, Tarone G, Brancaccio M.

Nat Commun. 2017 Nov 21;8(1):1636. doi: 10.1038/s41467-017-01829-1.

8.

The protein restriction mimetic Resveratrol is an autophagy inducer stronger than amino acid starvation in ovarian cancer cells.

Ferraresi A, Titone R, Follo C, Castiglioni A, Chiorino G, Dhanasekaran DN, Isidoro C.

Mol Carcinog. 2017 Dec;56(12):2681-2691. doi: 10.1002/mc.22711. Epub 2017 Sep 7.

PMID:
28856729
9.

A promoter-proximal transcript targeted by genetic polymorphism controls E-cadherin silencing in human cancers.

Pisignano G, Napoli S, Magistri M, Mapelli SN, Pastori C, Di Marco S, Civenni G, Albino D, Enriquez C, Allegrini S, Mitra A, D'Ambrosio G, Mello-Grand M, Chiorino G, Garcia-Escudero R, Varani G, Carbone GM, Catapano CV.

Nat Commun. 2017 May 30;8:15622. doi: 10.1038/ncomms15622.

10.

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.

Pignochino Y, Capozzi F, D'Ambrosio L, Dell'Aglio C, Basiricò M, Canta M, Lorenzato A, Vignolo Lutati F, Aliberti S, Palesandro E, Boccone P, Galizia D, Miano S, Chiabotto G, Napione L, Gammaitoni L, Sangiolo D, Benassi MS, Pasini B, Chiorino G, Aglietta M, Grignani G.

Mol Cancer. 2017 Apr 28;16(1):86. doi: 10.1186/s12943-017-0652-5.

11.

Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells.

Vitiello M, Tuccoli A, D'Aurizio R, Sarti S, Giannecchini L, Lubrano S, Marranci A, Evangelista M, Peppicelli S, Ippolito C, Barravecchia I, Guzzolino E, Montagnani V, Gowen M, Mercoledi E, Mercatanti A, Comelli L, Gurrieri S, Wu LW, Ope O, Flaherty K, Boland GM, Hammond MR, Kwong L, Chiariello M, Stecca B, Zhang G, Salvetti A, Angeloni D, Pitto L, Calorini L, Chiorino G, Pellegrini M, Herlyn M, Osman I, Poliseno L.

Oncotarget. 2017 Apr 11;8(15):25395-25417. doi: 10.18632/oncotarget.15915.

12.

Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line.

Peraldo Neia C, Cavalloni G, Chiorino G, Ostano P, Aglietta M, Leone F.

Oncotarget. 2016 Dec 27;7(52):86766-86780. doi: 10.18632/oncotarget.13575.

13.

lncRNAs as Novel Indicators of Patients' Prognosis in Stage I Epithelial Ovarian Cancer: A Retrospective and Multicentric Study.

Martini P, Paracchini L, Caratti G, Mello-Grand M, Fruscio R, Beltrame L, Calura E, Sales G, Ravaggi A, Bignotti E, Odicino FE, Sartori E, Perego P, Katsaros D, Craparotta I, Chiorino G, Cagnin S, Mannarino L, Ceppi L, Mangioni C, Ghimenti C, D'Incalci M, Marchini S, Romualdi C.

Clin Cancer Res. 2017 May 1;23(9):2356-2366. doi: 10.1158/1078-0432.CCR-16-1402. Epub 2016 Nov 8.

14.

MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression.

Dallavalle C, Albino D, Civenni G, Merulla J, Ostano P, Mello-Grand M, Rossi S, Losa M, D'Ambrosio G, Sessa F, Thalmann GN, Garcia-Escudero R, Zitella A, Chiorino G, Catapano CV, Carbone GM.

J Clin Invest. 2016 Dec 1;126(12):4585-4602. doi: 10.1172/JCI86505. Epub 2016 Nov 7.

15.

Resveratrol inhibits IL-6-induced ovarian cancer cell migration through epigenetic up-regulation of autophagy.

Ferraresi A, Phadngam S, Morani F, Galetto A, Alabiso O, Chiorino G, Isidoro C.

Mol Carcinog. 2017 Mar;56(3):1164-1181. doi: 10.1002/mc.22582. Epub 2016 Nov 3.

PMID:
27787915
16.

Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages.

Raggi C, Correnti M, Sica A, Andersen JB, Cardinale V, Alvaro D, Chiorino G, Forti E, Glaser S, Alpini G, Destro A, Sozio F, Di Tommaso L, Roncalli M, Banales JM, Coulouarn C, Bujanda L, Torzilli G, Invernizzi P.

J Hepatol. 2017 Jan;66(1):102-115. doi: 10.1016/j.jhep.2016.08.012. Epub 2016 Sep 1.

17.

Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma.

Cavalloni G, Peraldo-Neia C, Varamo C, Chiorino G, Sassi F, Aglietta M, Leone F.

Oncotarget. 2016 Aug 9;7(32):52354-52363. doi: 10.18632/oncotarget.10587.

18.

Dual tumor suppressing and promoting function of Notch1 signaling in human prostate cancer.

Lefort K, Ostano P, Mello-Grand M, Calpini V, Scatolini M, Farsetti A, Dotto GP, Chiorino G.

Oncotarget. 2016 Jul 26;7(30):48011-48026. doi: 10.18632/oncotarget.10333.

19.

Class II phosphoinositide 3-kinase C2β regulates a novel signaling pathway involved in breast cancer progression.

Chikh A, Ferro R, Abbott JJ, Piñeiro R, Buus R, Iezzi M, Ricci F, Bergamaschi D, Ostano P, Chiorino G, Lattanzio R, Broggini M, Piantelli M, Maffucci T, Falasca M.

Oncotarget. 2016 Apr 5;7(14):18325-45. doi: 10.18632/oncotarget.7761.

20.

Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation.

Cavalloni G, Peraldo-Neia C, Sassi F, Chiorino G, Sarotto I, Aglietta M, Leone F.

BMC Cancer. 2016 Feb 11;16:90. doi: 10.1186/s12885-016-2136-1.

21.

Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient.

Cavalloni G, Peraldo-Neia C, Varamo C, Casorzo L, Dell'Aglio C, Bernabei P, Chiorino G, Aglietta M, Leone F.

Tumour Biol. 2016 Mar;37(3):4041-52. doi: 10.1007/s13277-015-4215-3. Epub 2015 Oct 20.

22.

Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts.

Pinessi D, Ostano P, Borsotti P, Bello E, Guffanti F, Bizzaro F, Frapolli R, Bani MR, Chiorino G, Taraboletti G, Resovi A.

Connect Tissue Res. 2015;56(5):355-63. doi: 10.3109/03008207.2015.1045065. Epub 2015 Jun 15.

PMID:
25943461
23.

A randomized double-blind placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or "chemopromotion"?

Gontero P, Marra G, Soria F, Oderda M, Zitella A, Baratta F, Chiorino G, Gregnanin I, Daniele L, Cattel L, Frea B, Brusa P.

Prostate. 2015 Aug 1;75(11):1177-86. doi: 10.1002/pros.22999. Epub 2015 Apr 20.

PMID:
25893930
24.

Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations.

Ricci F, Bizzaro F, Cesca M, Guffanti F, Ganzinelli M, Decio A, Ghilardi C, Perego P, Fruscio R, Buda A, Milani R, Ostano P, Chiorino G, Bani MR, Damia G, Giavazzi R.

Cancer Res. 2014 Dec 1;74(23):6980-90. doi: 10.1158/0008-5472.CAN-14-0274. Epub 2014 Oct 10.

25.

A novel Nrf2-miR-29-desmocollin-2 axis regulates desmosome function in keratinocytes.

Kurinna S, Schäfer M, Ostano P, Karouzakis E, Chiorino G, Bloch W, Bachmann A, Gay S, Garrod D, Lefort K, Dotto GP, Beer HD, Werner S.

Nat Commun. 2014 Oct 6;5:5099. doi: 10.1038/ncomms6099.

PMID:
25283360
26.

Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2.

Borsotti P, Ghilardi C, Ostano P, Silini A, Dossi R, Pinessi D, Foglieni C, Scatolini M, Lacal PM, Ferrari R, Moscatelli D, Sangalli F, D'Atri S, Giavazzi R, Bani MR, Chiorino G, Taraboletti G.

Pigment Cell Melanoma Res. 2015 Jan;28(1):73-81. doi: 10.1111/pcmr.12319. Epub 2014 Oct 13.

PMID:
25256553
27.

Wiring miRNAs to pathways: a topological approach to integrate miRNA and mRNA expression profiles.

Calura E, Martini P, Sales G, Beltrame L, Chiorino G, D'Incalci M, Marchini S, Romualdi C.

Nucleic Acids Res. 2014 Jun;42(11):e96. doi: 10.1093/nar/gku354. Epub 2014 May 6.

28.

iASPP is a novel autophagy inhibitor in keratinocytes.

Chikh A, Sanzà P, Raimondi C, Akinduro O, Warnes G, Chiorino G, Byrne C, Harwood CA, Bergamaschi D.

J Cell Sci. 2014 Jul 15;127(Pt 14):3079-93. doi: 10.1242/jcs.144816. Epub 2014 Apr 28.

29.

Multifactorial ERβ and NOTCH1 control of squamous differentiation and cancer.

Brooks YS, Ostano P, Jo SH, Dai J, Getsios S, Dziunycz P, Hofbauer GF, Cerveny K, Chiorino G, Lefort K, Dotto GP.

J Clin Invest. 2014 May;124(5):2260-76. doi: 10.1172/JCI72718. Epub 2014 Apr 17.

30.

Current understanding of the thrombospondin-1 interactome.

Resovi A, Pinessi D, Chiorino G, Taraboletti G.

Matrix Biol. 2014 Jul;37:83-91. doi: 10.1016/j.matbio.2014.01.012. Epub 2014 Jan 27. Review.

31.

Identification of two regions in the p140Cap adaptor protein that retain the ability to suppress tumor cell properties.

Sharma N, Repetto D, Aramu S, Grasso S, Russo I, Fiorentino A, Mello-Grand M, Cabodi S, Singh V, Chiorino G, Turco E, Stefano PD, Defilippi P.

Am J Cancer Res. 2013 Jun 20;3(3):290-301. Print 2013.

32.

ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-κB and drives prostate cancer progression.

Longoni N, Sarti M, Albino D, Civenni G, Malek A, Ortelli E, Pinton S, Mello-Grand M, Ostano P, D'Ambrosio G, Sessa F, Garcia-Escudero R, Thalmann GN, Chiorino G, Catapano CV, Carbone GM.

Cancer Res. 2013 Jul 15;73(14):4533-47. doi: 10.1158/0008-5472.CAN-12-4537. Epub 2013 May 16.

33.

p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis.

Matin RN, Chikh A, Chong SL, Mesher D, Graf M, Sanza' P, Senatore V, Scatolini M, Moretti F, Leigh IM, Proby CM, Costanzo A, Chiorino G, Cerio R, Harwood CA, Bergamaschi D.

J Exp Med. 2013 Mar 11;210(3):581-603. doi: 10.1084/jem.20121439. Epub 2013 Feb 18.

34.

Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy.

Ghimenti C, Mello-Grand M, Grosso E, Scatolini M, Regolo L, Zambelli A, Chiorino G.

Exp Ther Med. 2013 Mar;5(3):902-906. Epub 2012 Dec 24.

35.

Nicotinamide phosphoribosyltransferase (NAMPT) is over-expressed in melanoma lesions.

Maldi E, Travelli C, Caldarelli A, Agazzone N, Cintura S, Galli U, Scatolini M, Ostano P, Miglino B, Chiorino G, Boldorini R, Genazzani AA.

Pigment Cell Melanoma Res. 2013 Jan;26(1):144-6. doi: 10.1111/pcmr.12037. Epub 2012 Nov 12. No abstract available.

PMID:
23051650
36.

Comparison of microarray platforms for measuring differential microRNA expression in paired normal/cancer colon tissues.

Callari M, Dugo M, Musella V, Marchesi E, Chiorino G, Grand MM, Pierotti MA, Daidone MG, Canevari S, De Cecco L.

PLoS One. 2012;7(9):e45105. doi: 10.1371/journal.pone.0045105. Epub 2012 Sep 13. Erratum in: PLoS One. 2013;8(5). doi:10.1371/annotation/c38405cc-dc33-424e-bfcb-14de73f5c8c8.

37.

Overexpression of CD157 contributes to epithelial ovarian cancer progression by promoting mesenchymal differentiation.

Morone S, Lo-Buono N, Parrotta R, Giacomino A, Nacci G, Brusco A, Larionov A, Ostano P, Mello-Grand M, Chiorino G, Ortolan E, Funaro A.

PLoS One. 2012;7(8):e43649. doi: 10.1371/journal.pone.0043649. Epub 2012 Aug 20.

38.

Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer.

Marchini S, Fruscio R, Clivio L, Beltrame L, Porcu L, Fuso Nerini I, Cavalieri D, Chiorino G, Cattoretti G, Mangioni C, Milani R, Torri V, Romualdi C, Zambelli A, Romano M, Signorelli M, di Giandomenico S, D'Incalci M.

Eur J Cancer. 2013 Jan;49(2):520-30. doi: 10.1016/j.ejca.2012.06.026. Epub 2012 Aug 13.

PMID:
22897840
39.

Aberrant expression of the neuronal-specific protein DCDC2 promotes malignant phenotypes and is associated with prostate cancer progression.

Longoni N, Kunderfranco P, Pellini S, Albino D, Mello-Grand M, Pinton S, D'Ambrosio G, Sarti M, Sessa F, Chiorino G, Catapano CV, Carbone GM.

Oncogene. 2013 May 2;32(18):2315-24, 2324.e1-4. doi: 10.1038/onc.2012.245. Epub 2012 Jun 25.

PMID:
22733135
40.

A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma.

Uboldi S, Calura E, Beltrame L, Fuso Nerini I, Marchini S, Cavalieri D, Erba E, Chiorino G, Ostano P, D'Angelo D, D'Incalci M, Romualdi C.

PLoS One. 2012;7(4):e35423. doi: 10.1371/journal.pone.0035423. Epub 2012 Apr 16.

41.

ESE3/EHF controls epithelial cell differentiation and its loss leads to prostate tumors with mesenchymal and stem-like features.

Albino D, Longoni N, Curti L, Mello-Grand M, Pinton S, Civenni G, Thalmann G, D'Ambrosio G, Sarti M, Sessa F, Chiorino G, Catapano CV, Carbone GM.

Cancer Res. 2012 Jun 1;72(11):2889-900. doi: 10.1158/0008-5472.CAN-12-0212. Epub 2012 Apr 13.

42.

The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression.

Babbio F, Pistore C, Curti L, Castiglioni I, Kunderfranco P, Brino L, Oudet P, Seiler R, Thalman GN, Roggero E, Sarti M, Pinton S, Mello-Grand M, Chiorino G, Catapano CV, Carbone GM, Bonapace IM.

Oncogene. 2012 Nov 15;31(46):4878-87. doi: 10.1038/onc.2011.641. Epub 2012 Feb 13.

PMID:
22330138
43.

Cross-analysis of gene and miRNA genome-wide expression profiles in human fibroblasts at different stages of transformation.

Ostano P, Bione S, Belgiovine C, Chiodi I, Ghimenti C, Scovassi AI, Chiorino G, Mondello C.

OMICS. 2012 Jan-Feb;16(1-2):24-36. doi: 10.1089/omi.2011.0049.

44.

Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells.

Cutrupi S, Reineri S, Panetto A, Grosso E, Caizzi L, Ricci L, Friard O, Agati S, Scatolini M, Chiorino G, Lykkesfeldt AE, De Bortoli M.

Oncogene. 2012 Oct 4;31(40):4353-61. doi: 10.1038/onc.2011.627. Epub 2012 Jan 16. Erratum in: Oncogene. 2012 Oct 4;31(40):4420.

45.

iASPP/p63 autoregulatory feedback loop is required for the homeostasis of stratified epithelia.

Chikh A, Matin RN, Senatore V, Hufbauer M, Lavery D, Raimondi C, Ostano P, Mello-Grand M, Ghimenti C, Bahta A, Khalaf S, Akgül B, Braun KM, Chiorino G, Philpott MP, Harwood CA, Bergamaschi D.

EMBO J. 2011 Sep 6;30(20):4261-73. doi: 10.1038/emboj.2011.302.

46.

Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.

Uboldi S, Bernasconi S, Romano M, Marchini S, Fuso Nerini I, Damia G, Ganzinelli M, Marangon E, Sala F, Clivio L, Chiorino G, Di Giandomenico S, Rocchi M, Capozzi O, Margison GP, Watson AJ, Caccuri AM, Pastore A, Fossati A, Mantovani R, Grosso F, Tercero JC, Erba E, D'Incalci M.

Int J Cancer. 2012 Jul 1;131(1):59-69. doi: 10.1002/ijc.26340. Epub 2011 Aug 30.

47.

Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections.

Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, Fuso Nerini I, Mangioni C, Cattoretti G, Clivio L, Beltrame L, Katsaros D, Scarampi L, Menato G, Perego P, Chiorino G, Buda A, Romualdi C, D'Incalci M.

Lancet Oncol. 2011 Mar;12(3):273-85. doi: 10.1016/S1470-2045(11)70012-2. Epub 2011 Feb 21.

PMID:
21345725
48.

Eps8 involvement in neuregulin1-ErbB4 mediated migration in the neuronal progenitor cell line ST14A.

Fregnan F, Petrov V, Garzotto D, De Marchis S, Offenhäuser N, Grosso E, Chiorino G, Perroteau I, Gambarotta G.

Exp Cell Res. 2011 Apr 1;317(6):757-69. doi: 10.1016/j.yexcr.2011.01.023. Epub 2011 Jan 31.

49.

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer.

Peraldo-Neia C, Migliardi G, Mello-Grand M, Montemurro F, Segir R, Pignochino Y, Cavalloni G, Torchio B, Mosso L, Chiorino G, Aglietta M.

BMC Cancer. 2011 Jan 25;11:31. doi: 10.1186/1471-2407-11-31.

50.

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.

Pignochino Y, Sarotto I, Peraldo-Neia C, Penachioni JY, Cavalloni G, Migliardi G, Casorzo L, Chiorino G, Risio M, Bardelli A, Aglietta M, Leone F.

BMC Cancer. 2010 Nov 18;10:631. doi: 10.1186/1471-2407-10-631.

Supplemental Content

Loading ...
Support Center